HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3

HAEMONETICS CORP

Financials through Q1 FY2027, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 6, 2026

$118.73+0.45 (+0.38%)

Close on Oct 19, 2026

Market cap: $5.43B
P/E (TTM): 57.9
Dividend yield: –

HAEMONETICS CORP income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-28	FY 2025 2025-03-29	FY 2024 2024-03-30	FY 2023 2023-04-01	FY 2022 2022-04-02	FY 2021 2021-04-03	FY 2020 2020-03-28	FY 2019 2019-03-30	FY 2018 2018-03-31	FY 2017 2017-04-01	FY 2016 2016-04-02	FY 2015 2015-03-28	FY 2014 2014-03-29	FY 2013 2013-03-30	FY 2012 2012-03-31	FY 2011 2011-04-02	FY 2010 2010-04-03	FY 2009 2009-03-28
Revenue	1,334	1,361	1,309	1,169	993	870	988	968	904	886	909	910	939	892	728	677	645	598
Cost of Revenue	546	612	618	554	488	473	504	550	492	508	503	476	470	464	359	321	308	290
Gross Profit	788	749	692	615	506	398	485	418	412	378	406	434	468	428	369	355	337	308
Research & Development	60	63	54	50	47	33	31	36	39	38	45	54	54	44	37	33	26	24
Selling, General & Admin	442	437	430	377	340	275	282	273	317	302	317	337	366	323	244	214	214	199
Advertising Expenses	7.40	7.70	7.10	7.20	4.40	2.70	4.30	4.50	3.10	2.50	3.90	4.50	3.60	4.60	4.50	2.80	1.60	–
Operating Expenses	631	527	527	459	425	308	381	334	356	398	450	394	422	372	280	245	254	223
Operating Income	157	222	165	156	81	90	103	84	56	-19	-44	41	46	56	89	111	83	86
Interest Expense	19	36	20	13	5.80	9.40	14	13	7.70	–	–	–	–	–	–	0.01	0.74	0.06
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.38	0.40	1.97
Other Non-Operating Income	-29	-9.75	-13	-15	-17	-17	-16	-9.91	-4.53	-8.10	-9.47	-9.38	-10	-6.54	0.74	-0.47	-2.01	-2.47
Merger & Restructuring Charges	3.11	14	14	0.66	4.23	1.44	3.59	0.40	31	22	23	37	49	11	5.86	4.48	–	–
Asset Impairment Charges	9.30	2.39	10	0.61	7.95	22	51	21	2.67	75	101	5.88	2.59	4.25	0	0	16	–
Gain (Loss) on Investments	–	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0.71	16	1.01	0.94	-9.60	-33	-8.08	0	8.00	0	0	-0.04	-0.29	-0.35	-0.77	-0.67	0.44	0.12
Legal Settlements	–	–	6.67	5.23	1.37	0.90	-0.70	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	128	212	152	141	64	73	87	74	60	-27	-53	31	36	50	89	110	81	85
Income Tax Expense	31	44	34	26	20	-6.56	11	19	14	-1.21	2.16	14	1.25	11	23	30	23	26
Net Income	97	168	118	115	43	79	77	55	46	-26	-56	17	35	39	67	80	58	59
EPS (Basic)(per share)	2.06	3.33	2.32	2.27	0.85	1.57	1.51	1.07	0.86	-0.51	-1.09	0.33	0.68	0.76	1.32	1.59	1.15	1.17
EPS (Diluted)(per share)	2.05	3.31	2.29	2.24	0.84	1.55	1.48	1.04	0.85	-0.51	-1.09	0.32	0.67	0.74	1.30	1.56	1.12	1.14
Shares Outstanding (Basic, Weighted)(shares)	47	50	51	51	51	51	51	52	53	52	51	52	52	51	51	50	51	51
Shares Outstanding (Diluted, Weighted)(shares)	47	51	51	51	51	51	52	53	54	52	51	52	52	52	52	51	52	52
EBITDA	268	337	262	249	178	174	214	193	145	70	46	127	128	122	139	159	127	122

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 27, 2026

Profitability, TTM

Gross margin: 59.0%
Operating margin: 11.9%
Net margin: 7.1%
Return on equity, FY2026: 12.0%

Financial strength

Current ratio: 3.08
Debt to equity: 1.40
Debt to assets: 49.6%
Cash to current liabilities: 84.9%

Valuation

P/E ratio: 57.9
Price to sales: 4.01
Price to book: 6.48
Dividend yield: –